Table 4 Different approaches used in bacterial OMVs for different therapeutic purposes
From: Prokaryotic microvesicles Ortholog of eukaryotic extracellular vesicles in biomedical fields
Bacterial Species | Cargo Loaded | Loading Method | Application | References |
|---|---|---|---|---|
Klebsiella pneumoniae | Doxorubicin-loaded OMVs | Incubation | Anti-tumor efficacy in non-small-cell lung cancer | [178] |
Escherichia coli | Loading indocyanine green to modified OMVs with a synthesized αvβ3 integrin targeting ligand and arginyl-glycyl-aspartic acid | The fusion effect and electrostatic interaction | Melanoma | [179] |
Escherichia coli | Spy ligation to factor hemoglobin protease on the surface of OMVs | Incubation | Vaccine design | [180] |
Escherichia coli | Melanin | Genetic engineering of parent bacteria | Cancer | [181] |
Escherichia coli | siRNA | Electroporation | Cancer therapy | [182] |
Escherichia coli | NanoLuc Luciferase enzyme | Genetic engineering | Bioluminescence Imaging | [183] |
Escherichia coli | Inhibitor of Indoleamine2,3-dioxygenase | Electroporation | Cancer Immunotherapy | [184] |
Escherichia coli | NanoLuc Luciferase enzyme | Genetic engineering | As modular nanodevices for biosensing and bioimaging | [185] |
Klebsiella pneumonia | Doxorubicin | Incubation | Anti-tumor in non-small-cell lung cancer | [178] |
Pseudomonas aeruginosa | Gold NPs | Electroporation | Drug delivery | [186] |
Escherichia coli | PD-1 Plasmid | Engineered to express the targeted polypeptide LyP1 | Cancer Immunotherapy | [187] |
Escherichia coli | Mesoporous silica nanoparticles loaded with 5-FU | Ultracentrifugation | Drug delivery system | [188] |
Acinetobacter aumannii | Antibiotics | ND | Vesicle-based drug efflux mechanism | [176] |
Salmonella typhimurium | Ovalbumin | Genetic manipulation | Maturation of human monocyte-derived dendritic cells | [189] |
Escherichia coli | Shiga toxin | Ultracentrifugation | Cytotoxicity assays | [190] |